This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Feuerstein's Biotech-Stock Mailbag

Welcome back to the Biotech-Stock Mailbag. This week, I'll tackle questions on Viropharma (VPHM), Indevus Pharmaceuticals (IDEV), ArQule (ARQL) and (briefly) Northfield Laboratories (NFLD).


James "Jimmy" T. writes: "Can you please give your perspective on Viropharma and Nastech Pharmaceuticals (NSTK)? Of the two, it looks like Viropharma is way undervalued and in the case of Nastech, it is way overpriced compared to sales."

I'm going to focus on Viropharma and leave Nastech for another Mailbag, mainly because Viropharma was dealt a big blow to its drug pipeline Friday.

Dosing of the company's hepatitis C drug HCV-796 was stopped after patients in an ongoing phase II study developed liver toxicity. Viropharma and its partner Wyeth (WYE) have not permanently shelved the HCV-796 yet, but a drug that causes liver toxicity, especially in hepatitis C patients, is an extremely serious problem.

It's unfortunate because HCV-796 appears to have a strong antiviral effect against the hepatitis C virus, but I have a hard time envisioning a scenario where HCV-796 survives this setback.

When Jimmy emailed me his question, HCV-796 was still a viable and promising drug in Viropharma's pipeline. In fact, I wrote this column on Thursday, so I had to revise it when the HCV-796 news hit Friday.

I can understand how Jimmy viewed Viropharma as undervalued prior to this recent setback. Second-quarter earnings easily topped Wall Street estimates and the company raised 2007 sales guidance for Vancocin, its treatment for gastrointestinal tract infections.

At Thursday's closing price of $10.22, Viropharma was trading at a price-to-earnings ratio of just 12 times estimated 2008 earnings, or 4 times estimated 2008 sales.

Cheap, right? Well, not exactly. The reason that investors were discounting Viropharma's valuation is because of worries that Vancocin would face generic competition next year. Vancocin gross margins are in the 90%-plus range and because of that the drug generates a good amount of cash flow for Viropharma.

That's great, but if a cheaper generic version of Vancocin is launched, Viropharma's operating business takes a big hit. You can see that playing out in the current analyst estimates: They have Viropharma earning $1.17 per share this year but only 86 cents per share in 2008.

1 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs